The estimated Net Worth of Larry Michael Mertz is at least $132 Tysiąc dollars as of 20 May 2024. Larry Mertz owns over 1,283 units of Accelerate Diagnostics Inc stock worth over $132,204 and over the last 2 years Larry sold AXDX stock worth over $0.
Larry has made over 7 trades of the Accelerate Diagnostics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Larry exercised 1,283 units of AXDX stock worth $2,066 on 20 May 2024.
The largest trade Larry's ever made was exercising 116,329 units of Accelerate Diagnostics Inc stock on 2 March 2023 worth over $187,290. On average, Larry trades about 25,063 units every 58 days since 2022. As of 20 May 2024 Larry still owns at least 82,114 units of Accelerate Diagnostics Inc stock.
You can see the complete history of Larry Mertz stock trades at the bottom of the page.
Larry's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.
Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg oraz Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include: